BUSINESS
Japan’s 1st Forteo Biosimilar Nears Market, Mochida Looks at Billion-Yen Sales
Mochida Pharmaceutical aims to rack up peak sales of several billion yen with its soon-to-launch biosimilar version of Forteo (teriparatide), which will be the first follow-on biologic in the Japanese osteoporosis market, Executive Managing Director Junichi Sakaki tells Jiho. The…
To read the full story
Related Article
- Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
November 27, 2019
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





